Ultime notizie per Saltbae Capital (OTC:CECBF) Azioni

Saltbae Capital Corp formerly CellCube Energy Storage Systems Inc is a Canadian company which acts as an integrated producer of vanadium and vanadium electrolytes for the energy storage industry. The principal activity is the exploration of its mineral properties in Canada and the United States. The company owns an interest in Bisoni-Mckay Property and Bisoni-Rio Property.

Saltbae Capital Corp

Reborn Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) reported quarterly losses of $(0.47) per share. This is a 21.67 percent increase over losses of $(0.60) per share from the same period last year. The company reported $1.69 million in sales this quarter. This is a 11.53 percent increase over sales of $1.52 million the same period last year.

Earnings

News

REBN

Reborn Coffee Q1 EPS $(0.47) Up From $(0.60) YoY, Sales $1.69M Up From $1.52M YoY

OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) reported quarterly losses of $(1.04) per share. The company reported $761.27 million in sales this quarter.

OSRH

OSR Holdings Q1 EPS $(1.04), Sales $761.27M

Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) has outperformed the market over the past 5 years by 4.89% on an annualized basis producing an average annual return of 19.55%. Currently, Bank of New York Mellon has a market capitalization of $64.46 billion. 
Buying $1000 In BK: If an investor had bought $1000 of BK stock 5 years ago, it would be worth $2,611.59 today based on a price of $90.10 for BK at the time of writing.
<h3>Bank of New York Mellon's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747776628_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Toll Brothers Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) released its second-quarter results after Tuesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/05/g45530143/toll-brothers-reports-fy-2025-second-quarter-results">from the quarter.</a>
The Details:&nbsp;Toll Brothers reported quarterly earnings of&nbsp;$3.50&nbsp;per share, which beat the analyst consensus estimate of&nbsp;$2.92&nbsp;by&nbsp;19.86%. Quarterly revenue came in at $2.71 billion,&nbsp;which beat the Street estimate of&nbsp;$2.48 billion. &nbsp;
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
For the second quarter, Toll Brothers reported: 
<ul class="wp-block-list">
<li>Home sales revenues were $2.71 billion, up 2% compared to last year&#8217;s second quarter; delivered homes were 2,899, up 10%.</li>
<li>Net signed contract value was $2.60 billion, down 11% compared to last year&#8217;s second quarter; contracted homes were 2,650, down 13%.</li>
<li>Backlog value was $6.84 billion at second quarter end, down 7% compared to last year&#8217;s second quarter; homes in backlog were 6,063, down 15%.</li>
<li>Adjusted home sales gross margin was 27.5%. </li>
</ul>
&#8220;We are pleased with our second quarter results, as we delivered earnings that significantly exceeded expectations. Despite a softer demand environment, we generated record second quarter home sales revenues of $2.71 billion, well above our guidance of $2.47 billion, and beat both our adjusted gross margin and SG&amp;A guidance,&#8221; said Douglas C. Yearley Jr., CEO of Toll Brothers.
TOL Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Toll Brothers stock was up 4.79% at $109.52 after-hours on Tuesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Movers

Real Estate

Toll Brothers Shares Are Up After Strong Q2 Results: EPS Beat, Revenues Beat

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully&nbsp;upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the "Notes"). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings (i) to fund the announced tender offers (collectively, the "Tender Offer") to purchase, for cash, its 3.150% Senior Notes due 2026, 4.750% Sustainability-Linked Senior Notes due 2027, 3.750% Sustainability-Linked Senior Notes due 2027, 7.875% Sustainability-Linked Senior Notes due 2029, 7.375% Sustainability-Linked Senior Notes due 2029 and 8.125% Sustainability-Linked Senior Notes due 2031&nbsp;(as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith and (iii) to the extent of any remaining proceeds, the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose.
The Notes consist of (i) Teva Pharmaceutical Finance Netherlands II B.V's ("Teva Finance II") €1,000,000,000 aggregate principal amount of 4.125% EUR-denominated Senior Notes maturing in 2031, (ii) Teva Pharmaceutical Finance Netherlands III B.V.'s ("Teva Finance III") $500,000,000 aggregate principal amount of 6.000% USD-denominated Senior Notes maturing in 2032 and (iii) Teva Pharmaceutical Finance Netherlands IV B.V.'s ("Teva Finance IV" and, together with Teva Finance II and Teva Finance III, the "Issuers") $700,000,000 aggregate principal amount of 5.750% USD-denominated Senior Notes maturing in 2030.
The settlement of the Notes is expected to occur on or about May 28, 2025, subject to customary closing conditions. The settlement of the Notes will satisfy the financing condition to the Tender Offer.

Offerings

TEVA

Teva Pharmaceutical Industries Announces It Upsized Its Offering From $2B And Priced ~$2.3B Of Its Senior Notes

OSUR

Orasure Technologies Files For Mixed Shelf Of Up To $300M

General

Equus Total Return Receives NYSE Notice Of Non-Compliance With Minimum Share Price Requirement

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks
Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in delaying IPF progression
Detailed safety analysis underscores favorable tolerability profile for deupirfenidone
PureTech plans to meet with FDA before end of Q3 2025, with the goal of initiating a Phase 3 trial by year-end
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54257865&amp;newsitemid=20250520345638&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=d3c41ff08eb102e88d128b2fd110bddc">PureTech Health plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>, LSE: PRTC))) (&quot;PureTech&quot; or the &quot;Company&quot;), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. The presentation provided further insights into the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretechs-deupirfenidone-lyt-100-slowed-lung-function-decline&amp;esheet=54257865&amp;newsitemid=20250520345638&amp;lan=en-US&amp;anchor=successful+Phase+2b+ELEVATE+IPF+trial&amp;index=2&amp;md5=df2f852b2e4793a012c9f61e73a222f2">successful Phase 2b ELEVATE IPF trial</a> of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone&#39;s treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis (IPF).

Biotech

PRTC

PureTech Presents Phase 2b Data For Deupirfenidone At ATS 2025, Showing Statistically Significant Slowing Of IPF Progression With Durable Effect Over 52 Weeks, Favorable Safety Profile, And Plans For FDA Meeting And Phase 3 Trial Launch By End Of 2025

Insider Trades

BDSX

Biodesix Form4 Filing Shows Jack Schuler Bought 4,723,239 Shares Of Stock At An Average Price Of $0.28/Share

Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) has outperformed the market over the past 15 years by 4.05% on an annualized basis producing an average annual return of 16.13%. Currently, Aon has a market capitalization of $78.26 billion. 
Buying $100 In AON: If an investor had bought $100 of AON stock 15 years ago, it would be worth $934.58 today based on a price of $362.43 for AON at the time of writing.
<h3>Aon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747775712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Aon 15 Years Ago Would Be Worth This Much Today

Shares of Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) are moving higher in Tuesday&#8217;s after-hours session after Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk announced that the company expects to purchase &#8220;a lot&#8221; of GPUs <a href="https://www.benzinga.com/news/25/04/44725803/musks-xai-aims-for-1-million-gpus-in-memphis-but-can-the-citys-grid-handle-a-27b-ai-power-surge">from the chip companies</a>.
What Happened: In an interview aired on CNBC&#8217;s &#8220;Closing Bell: Overtime,&#8221; Musk laid out a vision for the future that includes millions of fully autonomous robotaxi vehicles and Optimus bots. When asked how many GPUs the company will need to make that vision a reality, Musk said &#8220;quite a few.&#8221;
&#8220;We expect to still buy a lot of GPUs from Nvidia, some from AMD, and maybe from others,&#8221; Musk said. &#8220;As long as Nvidia is better than what we make, we&#8217;ll keep buying from Nvidia.&#8221;
Musk told CNBC that his vision is less than five years away. He also noted that his AI company xAI plans to continue buying GPUs from Nvidia. He highlighted the AI company&#8217;s training cluster, which he believes is the most powerful in the world right now, with over 200,000 GPUs at its facility in Memphis. 
Musk also told CNBC that xAI is in the process of building a second location that will feature one million Nvidia Blackwell GPUs, expected to be completed in the next six to nine months.
&#8220;It will be the first gigawatt-class training cluster in the world,&#8221; he said.
In after-hours at the time of publication on Tuesday, <a href="http://benzinga.com/quote/AMD">AMD shares</a> were up 0.77% at $114.38 and <a href="http://benzinga.com/quote/nvda">Nvidia shares</a> were narrowly higher, up 0.11% at $134.52 at last check, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Nvidia.

Tech

NVDA

TSLA

AMD, Nvidia Shares Jump After Musk Highlights xAI's GPU Needs: 'We Expect To Still Buy A Lot'

<a href="https://www.wsj.com/articles/wolfspeed-prepares-to-file-for-bankruptcy-within-weeks-7bd98040">https://www.wsj.com/articles/wolfspeed-prepares-to-file-for-bankruptcy-within-weeks-7bd98040</a>

WOLF

' Wolfspeed Prepares to File for Bankruptcy Within Weeks'- WSJ

<h3>Gainers</h3>
<ul>
<li>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) shares moved upwards by 8.3% to $1.31 during Tuesday's after-market session. The company's market cap stands at $29.9 million. </li>
<li>Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) shares moved upwards by 6.34% to $18.1. The market value of their outstanding shares is at $930.8 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) stock rose 5.8% to $0.97. The market value of their outstanding shares is at $5.1 million. As per the news, the Q1 earnings report came out today. </li>
<li>Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) shares moved upwards by 5.63% to $110.4. The company's market cap stands at $11.0 billion. The company's, Q2 earnings came out today. </li>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) shares moved upwards by 4.98% to $0.39. The company's market cap stands at $16.7 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares rose 4.81% to $6.75. The market value of their outstanding shares is at $1.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 17.6% to $0.35 during Tuesday's after-market session. The company's market cap stands at $7.1 million. </li>
<li>Outdoor Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) shares fell 12.16% to $1.59. The market value of their outstanding shares is at $188.8 million. </li>
<li>Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares decreased by 10.26% to $33.0. The company's market cap stands at $1.2 billion. </li>
<li>Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares fell 9.23% to $12.3. The market value of their outstanding shares is at $84.1 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) stock declined by 8.47% to $1.19. The company's market cap stands at $9.4 million. As per the news, the FY earnings report came out today. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) stock fell 5.31% to $0.4. The company's market cap stands at $2.7 million. As per the press release, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AYRO

BGFV

LVLU

MTEN

POWW

SDHC

SHCO

XWEL

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 39.5% to $0.38 during Tuesday's after-market session. The company's market cap stands at $55.3 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock rose 26.37% to $0.16. The company's, Q1 earnings came out 3 days ago. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock rose 15.6% to $0.81. The market value of their outstanding shares is at $8.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock rose 9.8% to $5.61. The market value of their outstanding shares is at $510.8 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock rose 7.23% to $0.44. The market value of their outstanding shares is at $12.1 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock increased by 6.7% to $0.52. The market value of their outstanding shares is at $53.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 9.0% to $5.49 during Tuesday's after-market session. The market value of their outstanding shares is at $83.5 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.46% to $4.2. The company's market cap stands at $4.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 6.21% to $11.18. The company's market cap stands at $206.7 million. </li>
<li>HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) stock declined by 5.95% to $1.9. The company's market cap stands at $95.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 5.94% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock decreased by 5.77% to $0.66. The market value of their outstanding shares is at $92.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HLVX

HSCS

INTS

MTVA

ONMD

OPRX

PTPI

VNRX

XTNT

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock moved upwards by 8.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $21.9 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock moved upwards by 6.58% to $0.42. The market value of their outstanding shares is at $5.2 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares rose 6.28% to $0.33. The company's market cap stands at $8.0 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares rose 5.73% to $3.22. The market value of their outstanding shares is at $109.8 million. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) shares rose 4.93% to $2.55. The company's market cap stands at $127.6 million. The company's, Q1 earnings came out today. </li>
<li>GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) stock rose 4.8% to $1.09. The company's market cap stands at $281.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) stock fell 8.6% to $17.92 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock fell 7.33% to $0.82. The market value of their outstanding shares is at $2.5 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) shares fell 7.0% to $0.65. The market value of their outstanding shares is at $8.7 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock decreased by 6.78% to $0.16. The company's market cap stands at $22.8 million. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) stock declined by 5.95% to $0.95. The market value of their outstanding shares is at $7.1 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) stock fell 5.01% to $0.87. The company's market cap stands at $17.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGO

CTRI

DXST

FBGL

NEOV

PSIG

SFHG

UGRO

XPON

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) stock moved upwards by 9.5% to $1.38 during Tuesday's after-market session. The market value of their outstanding shares is at $15.7 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) stock increased by 8.78% to $0.52. The market value of their outstanding shares is at $16.0 million. </li>
<li>Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) stock increased by 6.49% to $5.9. The market value of their outstanding shares is at $964.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) shares moved upwards by 5.38% to $0.47. The company's market cap stands at $67.9 million. </li>
<li>Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) stock increased by 5.2% to $171.27. The market value of their outstanding shares is at $29.5 billion. The company's, Q2 earnings came out today. </li>
<li>Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) shares increased by 5.0% to $1.26. The company's market cap stands at $299.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares fell 46.0% to $1.69 during Tuesday's after-market session. The company's market cap stands at $263.0 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares fell 14.97% to $2.0. The market value of their outstanding shares is at $51.6 million. </li>
<li>QXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) stock declined by 8.02% to $16.88. The market value of their outstanding shares is at $8.7 billion. </li>
<li>Key Tronic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) stock declined by 7.61% to $2.89. The market value of their outstanding shares is at $31.1 million. </li>
<li>Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) stock declined by 7.41% to $3.5. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) shares fell 6.58% to $7.53. The company's market cap stands at $70.9 million. As per the news, the Q1 earnings report came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIFR

EVLV

GREE

INUV

KEYS

KTCC

PCLA

TZUP

12 Information Technology Stocks Moving In Tuesday's After-Market Session

Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>)&nbsp;("Garrett" or the "Company"), a leading differentiated automotive technology provider, today announced a proposed secondary public offering of 17,000,000 shares of the Company's common stock held by certain entities managed by affiliates of Oaktree Capital Management, L.P., Centerbridge Partners, L.P. and Cyrus Capital Partners, L.P. (collectively, the "Selling Stockholders"). The underwriters will have a 30-day option to purchase at their own election up to an additional 2,550,000 shares of common stock from the Selling Stockholders. The Selling Stockholders will receive all of the net proceeds from the proposed offering. The Company is not selling any shares and will not receive any proceeds from the proposed offering.
Garrett has authorized the concurrent purchase from the underwriters of approximately 2 million shares of common stock as part of the secondary public offering (the "Repurchase"), subject to the completion of the offering, subject to a maximum aggregate repurchase amount of $25 million. The Repurchase is part of the Company's existing $250 million share repurchase program. The underwriters will not receive any compensation for the shares being repurchased by the Company pursuant to the Repurchase.

Buybacks

Garrett Motion Announces 17M Share Secondary Offering By Oaktree, Centerbridge, And Cyrus Capital And $25M Concurrent Share Repurchase Under Existing Buyback Program

Management

MTUS

Metallus Promotes Kristopher R. Westbrooks To President And COO And John M. Zaranec To CFO, Effective June 16, 2025

CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/05/ac45529780/cxapp-inc-nasdaq-cxai-reports-strong-q125-customer-success-metrics-and-adoption-of-agentic-ai-bas"> from the report. </a>
The Details: CXApp reported quarterly losses of eight cents per share, which beat the analyst consensus estimate of losses of 24 cents and is up from losses of 34 cents from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
For the first quarter, CXApp reported: 
<ul class="wp-block-list">
<li>ARR Expansion Growth of more than 130% and renewals for three large Fortune 500 clients</li>
<li>Subscription to One time Revenue split of 99%, up from 87% in the first quarter of 2024.</li>
<li>Gross Margin of 88%, up from 82% in the first quarter of 2024.</li>
</ul>
&#8220;The CXAI platform anchored on customer experience (CX) and artificial intelligence (AI) is the most advanced technology solution solving the biggest problems in our industry post the pandemic — the Return to Office (RTO) and Employee Engagement. The first quarter in 2025 has seen a resurgence of RTO mandates and an increased interest in Agentic AI solutions that are transformational to employee experiences,&#8221; CEO Khurram Sheikh commented.
CXAI Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, CXApp stock was down 3.60% at $1.34 after-hours on Tuesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image: Shutterstock

CXAI

CXApp Reports Better-Than-Expected Q1 Earnings: Details

In the current market session, Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) share price is at $349.50, after a 0.87% drop. Over the past month, the stock spiked by 20.03%, but over the past year, it actually decreased by 1.81%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1747774830_0.png" alt="Past Year Chart" />

<h3>Evaluating Caterpillar P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Caterpillar has a lower P/E than the aggregate P/E of 51.5 of the Machinery industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747774830_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Caterpillar

Saltbae Capital

Comments

Saltbae Capital

Notizie

Ultime notizie per Saltbae Capital (OTC:CECBF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO